HIGHLIGHTS
- who: Madison M. Rose and colleagues from the Division of Endocrinology, Metabolism, and Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Mail Stop, Aurora, CO, USA have published the article: BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer, in the Journal: (JOURNAL)
- what: This study provides evidence that combined and MEK1/2 inhibition is a promising therapeutic option for patients with advanced thyroid cancer and identifies induction as a potential biomarker of response. The authors elucidated the mechanism(s) by which inhibition of the Src and the MAPK . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.